| abstract |
CHARACTERIZED BECAUSE IT INCLUDES: A) A PROTEINASE INHIBITOR, PREFERABLY REFERING TO N-TERT-BUTIL-DECAHIDRO-2- [2- (R) -HIDROXI-4-FENIL-3 (S) [[N- (2-QUINOLILCARBONIL) -L-ASPARRAGINYL] AMINO] BUTYL] - (4aS, 8aS) -ISOQUINOLINE-3 (S) CARBOXAMIDE; B) A PHARMACEUTICALLY ACCEPTABLE CARRIER, CONTAINING A C8-C10 FATTY ACID MONOGLYCERIDE, OF ACID INDEX � 0.04, WHERE THE CONCENTRATION OF THE MONOGLYCERID SUFFICIENT TO DISSOLVE (A) IS APPROXIMATELY 3; C) POLIVINILPIRROLIDONA; D) FROM 0.01% TO 0.05% OF DL-O-TOCOFEROL. THESE GLYCERIDES USED AS BEARING COMPONENTS OF THE FORMULATION, SOLVE THE EXISTING DIFFICULTIES DUE TO THE HYDROPHOBIC AND / OR LIPOPHILIC CHARACTER OF (A), IN SUCH A WAY THAT IT INHIBITS PROTEASES OF VIRICALLY ASPARTATE CAUSES, USEFUL PREFERABLY FROM HIV |